Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat ...

Optimal treatment of MG depends on correct subclassification of the disease in all individual patients. This includes classification according to autoantibody (AChR, MuSK, titin, other), thymus ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

This week we are going to discuss a topic that we had briefly touched on earlier, the neurologic autoimmune conditions: myasthenia gravis and Lambert Eaton Syndrome (LEMS). To review: Myasthenia ...

Treatment with inebilizumab was associated with continued improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) generalized myasthenia gravis (gMG), according to 52-week ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Neurologist Susan W. Lee, DO, answers common questions about this treatment option for myasthenia gravis. Intravenous immunoglobulin (IVIG) is a pooled collection of antibodies derived from donors ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...